Valacyclovir Prophylaxis Versus Preemptive Valganciclovir Therapy to Prevent Cytomegalovirus Disease After Renal Transplantation
Top Cited Papers
Open Access
- 1 January 2008
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 8 (1) , 69-77
- https://doi.org/10.1111/j.1600-6143.2007.02031.x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Cytomegalovirus in transplantation – challenging thestatus quoClinical Transplantation, 2007
- Human Cytomegalovirus Subverts the Functions of Monocytes, Impairing Chemokine-Mediated Migration and Leukocyte RecruitmentJournal of Virology, 2006
- Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapyReviews in Medical Virology, 2006
- Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral ProphylaxisTransplantation, 2006
- The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejectionJournal of Clinical Virology, 2006
- Rat Cytomegalovirus-Accelerated Transplant Vascular Sclerosis Is Reduced with Mutation of the Chemokine-Receptor R33American Journal of Transplantation, 2005
- Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantationDiabetologia, 2004
- Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survivalKidney International, 2004
- Measurement of Human Cytomegalovirus Loads by Quantitative Real-Time PCR for Monitoring Clinical Intervention in Transplant RecipientsJournal of Clinical Microbiology, 2003
- Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplantsThe Lancet, 2000